NCT04855617 is a clinical trial of Ocrelizumab in Multiple Sclerosis, sponsored by NYU Langone Health.

Who is sponsoring NCT04855617?

NCT04855617 is sponsored by NYU Langone Health.

What drugs are being tested in NCT04855617?

Interventions in NCT04855617: Ocrelizumab.

What condition does NCT04855617 study?

NCT04855617 studies Multiple Sclerosis.

Is NCT04855617 still recruiting?

NCT04855617 is currently completed. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT04855617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Completed Last updated 15 June 2023

What this trial tests

trial testing Ocrelizumab in Multiple Sclerosis in 122 participants. Completed in 1 October 2022.

Timeline

26 October 2020

Primary endpoint
1 October 2022

1 October 2022

Quick facts

Lead sponsor	NYU Langone Health
Status	Completed
Study type	OBSERVATIONAL
Enrollment	122
Start date	26 October 2020
Primary completion	1 October 2022
Estimated completion	1 October 2022
Sites	2 locations across United States

Drugs / interventions tested

Ocrelizumab (OCRELIZUMAB) — full drug profile →

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 80, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to determine whether symptom burden differs by time to infusion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS).
Kister I, Oh C, Douglas EA, Bacon TE, et al · · 2023 · cited 9× · PMID 37674871 · DOI 10.1212/cpj.0000000000200185

Verify or expand the search:

Other trials of Ocrelizumab

Trials testing the same drug.

NCT06677710 — IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis · Phase 1 · suspended
NCT07282574 — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrel · Phase 2 · recruiting
NCT06846281 — Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Scle · Phase 3 · recruiting
NCT07483450 — A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Rel · Phase 4 · recruiting
NCT06495593 — Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis · Phase 4 · enrolling by invitation

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04855617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04855617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing